# Actuate Therapeutics, Inc.: financial statements, quarterly

ACTU · Nasdaq · CIK 1652935 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/actu.md) · [Financials](/companies/actu/financials.md) · [Filings](/companies/actu/filings.md) · [Insiders](/companies/actu/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/actu/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $k | [5,762](/filings/0001683168-24-007971.md) | [6,646 d](/filings/0001683168-25-001581.md) | [6,860](/filings/0001683168-25-003705.md) | [4,373](/filings/0001683168-25-006159.md) | [3,757](/filings/0001683168-25-008323.md) | [3,686 d](/filings/0001683168-26-002257.md) | [3,220](/filings/0001683168-26-003909.md) | [2,765](/filings/0001683168-26-006472.md) | [2,178](/filings/0001683168-25-008323.md) | [2,130 d](/filings/0001683168-26-002257.md) | [2,565](/filings/0001683168-26-003909.md) | [2,067](/filings/0001683168-26-006472.md) |
| Operating income | $k | [(6,476)](/filings/0001683168-24-007971.md) | [(7,615) d](/filings/0001683168-25-001581.md) | [(7,773)](/filings/0001683168-25-003705.md) | [(5,435)](/filings/0001683168-25-006159.md) | [(5,393)](/filings/0001683168-25-008323.md) | [(6,559) d](/filings/0001683168-26-002257.md) | [(6,366)](/filings/0001683168-26-003909.md) | [(5,969)](/filings/0001683168-26-006472.md) | [(5,472)](/filings/0001683168-25-008323.md) | [(4,688) d](/filings/0001683168-26-002257.md) | [(5,706)](/filings/0001683168-26-003909.md) | [(4,907)](/filings/0001683168-26-006472.md) |
| Interest expense | $k | [5.1](/filings/0001683168-24-007971.md) | [5.1 d](/filings/0001683168-25-001581.md) | [5.1](/filings/0001683168-25-003705.md) | [5.1](/filings/0001683168-25-006159.md) | [3.5](/filings/0001683168-25-008323.md) | [5.1 d](/filings/0001683168-26-002257.md) | [5.1](/filings/0001683168-26-003909.md) | [5.1](/filings/0001683168-26-006472.md) | [5.1](/filings/0001683168-25-008323.md) | [5.1 d](/filings/0001683168-26-002257.md) | [5.1](/filings/0001683168-26-003909.md) | [5.1](/filings/0001683168-26-006472.md) |
| Net income | $k | [(6,338)](/filings/0001683168-24-007971.md) | [(7,612) d](/filings/0001683168-25-001581.md) | [(8,296)](/filings/0001683168-25-008323.md) | [(6,572)](/filings/0001683168-25-008323.md) | [(5,971)](/filings/0001683168-25-008323.md) | [(6,446) d](/filings/0001683168-26-002257.md) | [(6,317)](/filings/0001683168-26-006472.md) | [(5,949)](/filings/0001683168-26-006472.md) | [(5,407)](/filings/0001683168-25-008323.md) | [(4,554) d](/filings/0001683168-26-002257.md) | [(5,626)](/filings/0001683168-26-006472.md) | [(4,867)](/filings/0001683168-26-006472.md) |
| Diluted EPS | $ per share | [(4.31)](/filings/0001683168-24-007971.md) | not reported | [(5.40)](/filings/0001683168-25-003705.md) | [(4.20)](/filings/0001683168-25-006159.md) | [(0.55)](/filings/0001683168-25-008323.md) | not reported | [(0.32)](/filings/0001683168-26-003909.md) | [(0.30)](/filings/0001683168-26-006472.md) | [(0.25)](/filings/0001683168-25-008323.md) | not reported | [(0.24)](/filings/0001683168-26-003909.md) | [(0.20)](/filings/0001683168-26-006472.md) |
| Basic EPS | $ per share | [(4.31)](/filings/0001683168-24-007971.md) | not reported | [(5.40)](/filings/0001683168-25-003705.md) | [(4.20)](/filings/0001683168-25-006159.md) | [(0.55)](/filings/0001683168-25-008323.md) | not reported | [(0.32)](/filings/0001683168-26-003909.md) | [(0.30)](/filings/0001683168-26-006472.md) | [(0.25)](/filings/0001683168-25-008323.md) | not reported | [(0.24)](/filings/0001683168-26-003909.md) | [(0.20)](/filings/0001683168-26-006472.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | [0.4](/filings/0001683168-24-006623.md) | [13.5](/filings/0001683168-24-007971.md) | [8.6](/filings/0001683168-25-001581.md) | [3.9](/filings/0001683168-25-003705.md) | [6.5](/filings/0001683168-25-006159.md) | [16.9](/filings/0001683168-25-008323.md) | [13.2](/filings/0001683168-26-002257.md) | [8.1](/filings/0001683168-26-003909.md) | [4.4](/filings/0001683168-26-006472.md) |
| Current assets | $m | not reported | [3.0](/filings/0001683168-25-001581.md) | not reported | [0.5](/filings/0001683168-24-006623.md) | [14.3](/filings/0001683168-24-007971.md) | [9.2](/filings/0001683168-26-002257.md) | [4.2](/filings/0001683168-25-003705.md) | [6.7](/filings/0001683168-25-006159.md) | [17.4](/filings/0001683168-25-008323.md) | [13.6](/filings/0001683168-26-006472.md) | [8.5](/filings/0001683168-26-003909.md) | [4.7](/filings/0001683168-26-006472.md) |
| Total assets | $m | not reported | [3.0](/filings/0001683168-25-001581.md) | not reported | [1.7](/filings/0001683168-24-006623.md) | [14.3](/filings/0001683168-24-007971.md) | [9.3](/filings/0001683168-26-002257.md) | [4.5](/filings/0001683168-25-003705.md) | [7.0](/filings/0001683168-25-006159.md) | [17.7](/filings/0001683168-25-008323.md) | [14.0](/filings/0001683168-26-006472.md) | [8.9](/filings/0001683168-26-003909.md) | [5.2](/filings/0001683168-26-006472.md) |
| Current liabilities | $m | not reported | [6.9](/filings/0001683168-25-001581.md) | not reported | [20.1](/filings/0001683168-24-006623.md) | [8.5](/filings/0001683168-24-007971.md) | [8.8](/filings/0001683168-26-002257.md) | [9.2](/filings/0001683168-25-003705.md) | [9.2](/filings/0001683168-25-006159.md) | [6.4](/filings/0001683168-25-008323.md) | [5.7](/filings/0001683168-26-006472.md) | [4.7](/filings/0001683168-26-003909.md) | [3.8](/filings/0001683168-26-006472.md) |
| Total liabilities | $m | not reported | [8.4](/filings/0001683168-25-001581.md) | not reported | [21.8](/filings/0001683168-24-006623.md) | [8.9](/filings/0001683168-24-007971.md) | [9.2](/filings/0001683168-26-002257.md) | [9.6](/filings/0001683168-25-003705.md) | [9.6](/filings/0001683168-25-006159.md) | [6.8](/filings/0001683168-25-008323.md) | [6.1](/filings/0001683168-26-006472.md) | [5.1](/filings/0001683168-26-003909.md) | [4.2](/filings/0001683168-26-006472.md) |
| Shareholders' equity | $m | [(92.1)](/filings/0001683168-24-007971.md) | [(99.6)](/filings/0001683168-26-002257.md) | [(108)](/filings/0001683168-25-008323.md) | [(114)](/filings/0001683168-25-008323.md) | [5.4](/filings/0001683168-25-008323.md) | [0.1](/filings/0001683168-26-006472.md) | [(5.1)](/filings/0001683168-26-006472.md) | [(2.7)](/filings/0001683168-26-006472.md) | [10.9](/filings/0001683168-25-008323.md) | [7.9](/filings/0001683168-26-006472.md) | [3.8](/filings/0001683168-26-006472.md) | [1.0](/filings/0001683168-26-006472.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(5,638) d](/filings/0001683168-24-007971.md) | [(5,512) d](/filings/0001683168-25-001581.md) | [(5,248)](/filings/0001683168-25-003705.md) | [(2,674) d](/filings/0001683168-25-006159.md) | [(9,149) d](/filings/0001683168-25-008323.md) | [(4,772) d](/filings/0001683168-26-002257.md) | [(4,619)](/filings/0001683168-26-003909.md) | [(4,174) d](/filings/0001683168-26-006472.md) | [(6,678) d](/filings/0001683168-25-008323.md) | [(3,736) d](/filings/0001683168-26-002257.md) | [(5,017)](/filings/0001683168-26-003909.md) | [(4,405) d](/filings/0001683168-26-006472.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | period not labelled (2023-06-30) | period not labelled (2023-09-30) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [1.4](/filings/0001683168-24-006623.md) | [1.5](/filings/0001683168-24-007971.md) | [1.5](/filings/0001683168-25-003705.md) | [1.6](/filings/0001683168-25-006159.md) | [10.8](/filings/0001683168-25-008323.md) | [19.5](/filings/0001683168-26-003909.md) | [19.6](/filings/0001683168-26-006472.md) | [21.4](/filings/0001683168-25-008323.md) | [23.5](/filings/0001683168-26-003909.md) | [23.9](/filings/0001683168-26-006472.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 24,014,202 at 2026-08-13, from the cover of the [10-Q filed 2026-08-14](/filings/0001683168-26-006472.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.